• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ELI LILLY AND COMPANY HUMAPEN ERGO II FOR TREATMENT PURPOSES

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ELI LILLY AND COMPANY HUMAPEN ERGO II FOR TREATMENT PURPOSES Back to Search Results
Model Number MS9557
Device Problem Device Operates Differently Than Expected (2913)
Patient Problem No Code Available (3191)
Event Type  Injury  
Manufacturer Narrative
This is an initial report. A follow-up report will be submitted when the final evaluation is completed. This report is associated with 1819470-2016-00311, since there is more than one device implicated.
 
Event Description
Lilly case id: (b)(4). This report is associated with product complaint: (b)(4). This solicited case, reported by a consumer via a patient support program (psp), concerned a (b)(6)-old male patient of (b)(6) origin. Medical history and concomitant medications were not reported. The patient received human insulin isophane suspension 70%/ human insulin 30% (rdna origin) injection (humulin 70/30 iu300) cartridge via reusable pen (humapen ergo unknown body type), 20u in the morning and 18u evening daily, subcutaneously for the treatment of diabetes mellitus beginning in 2004. On an unreported date in 2012, the humapen ergo had an unspecified malfunction (product complaint (b)(4)/ lot unknown) and was replaced with a humapen ergo ii. Sometime in 2012 he was hospitalized to adjust his blood glucose and after half month he was discharged. In (b)(6) 2016, the injection screw would not move out on his humapen ergo ii (product complaint (b)(4)/lot 0803d06. On (b)(6) 2016 he was hospitalized to adjust his blood glucose again and would be discharged from the hospital on (b)(6) 2016. Additional information regarding corrective treatment was not provided. Outcome of the event was unknown. Human insulin isophane suspension 70%/ human insulin 30% treatment status was ongoing. The operator of the devices and his/her training status was unknown. The general device duration of use for the first device was approximately eight years, from 2004 to 2012 and the suspect device duration of use was eight years. The action taken with the suspect device was not provided and its return was not expected. The general device duration of use for the second device was approximately four years, beginning in 2012 and the suspect device duration of use was four years. The device remained in use, and would not be returned. The reporting consume did not know if the events were related to human insulin isophane suspension 70%/ human insulin 30% treatment and did not provide an assessment of relatedness for the suspect devices. No follow-up would be requested since the reporter refused to provide more information. Treating physician contact details not provided. Update 18-nov-2016: upon review of original source information from (b)(6) 2016 to update the 1st suspect device to a humapen ergo unknown body type; added the product complaint information and product complaint numbers to the case; updated the causality for the devices; updated the narrative; and completed the medwatch and (b)(6) required device reporting elements.
 
Manufacturer Narrative
No further follow up is planned. This report is associated with 1819470-2016-00311, since there is more than one device implicated. Evaluation summary: a male patient reported that the injection screw of his humapen ergo ii device was not moving out. He experienced abnormal blood glucose levels. The device was not returned to the manufacturer for investigation (batch number 0803d06, manufactured march 2008). Therefore, it could not be evaluated to confirm the complaint or presence of a malfunction. Malfunction unknown. A complaint history review of the batch did not identify any atypical findings with respect to injection screw/ratchet not moving or dose accuracy complaints. All humapen ergo ii devices are assessed for injection screw travel at the end of the manufacturing process, thus ensuring device functionality and dose accuracy with high probability. The patient used the device for approximately 4 years. The user manual states the humapen ergo ii has been designed to be used for up to 3 years after first use. In addition, the user manual instructs not to use the device if it appears broken or damaged and to contact lilly or your healthcare professional for a replacement pen. There is evidence of improper use. The patient used the device beyond its approved use life. It is unknown if this is relevant to the event of abnormal blood glucose levels.
 
Event Description
Lilly case id: (b)(6). This solicited case, reported by a consumer via a patient support program (psp), concerned a (b)(6) male patient of asian origin. Medical history and concomitant medications were not reported. The patient received human insulin isophane suspension 70%/ human insulin 30% (rdna origin) injection (humulin 70/30 iu300) cartridge via reusable pen (humapen ergo unknown body type), 20u in the morning and 18u evening daily, subcutaneously for the treatment of diabetes mellitus beginning in 2004. On an unreported date in 2012, the humapen ergo had an unspecified malfunction (product complaint 3829690/ lot unknown) and was replaced with a humapen ergo ii. Sometime in 2012 he was hospitalized to adjust his blood glucose and after half month he was discharged. In (b)(6) 2016, the injection screw would not move out on his humapen ergo ii (product complaint 3829691/lot 0803d06. On (b)(6) 2016 he was hospitalized to adjust his blood glucose again and would be discharged from the hospital on (b)(6) 2016. Additional information regarding corrective treatment was not provided. Outcome of the evens was unknown. Human insulin isophane suspension 70%/ human insulin 30% treatment status was ongoing. The operator of the devices and his/her training status was unknown. The general device duration of use for the first device was approximately eight years, from 2004 to 2012 and the suspect device duration of use was eight years. The device was not returned. The general device duration of use for the second device was approximately four years, beginning in 2012 and the suspect device duration of use was four years. The device was not returned. The reporting consume did not know if the events were related to human insulin isophane suspension 70%/ human insulin 30% treatment and did not provide an assessment of relatedness for the suspect devices. No follow-up would be requested since the reporter refused to provide more information. Treating physician contact details not provided. Update 18-nov-2016: upon review of original source information from 14-nov-2016 to update the 1st suspect device to a humapen ergo unknown body type; added the product complaint information and product complaint numbers to the case; updated the causality for the devices; updated the narrative; and completed the medwatch and european and canadian required device reporting elements. Update 14-dec-2016: additional information received on 13-dec-2016 from the global product complaint database added the device specific safety summary and manufactured date for the humapen ergo ii; added the device was not returned; updated the improper use and storage to yes; updated the medwatch and european and canadian required device reporting elements; and update the narrative. Update 15-dec-2016: additional information received on 17-nov-2016 from the product complaint database added no new information to the case. Update 15dec2016: additional information received on 14dec2016 from the global product complaint database added the device specific safety summary for the humapen ergo unknown body type; added the device was not returned; updated the improper use and storage to yes; updated the medwatch and european and (b)(4) required device reporting elements; and update the narrative.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NameHUMAPEN ERGO II
Type of DeviceFOR TREATMENT PURPOSES
Manufacturer (Section D)
ELI LILLY AND COMPANY
lilly corporate center
indianapolis IN 46285
Manufacturer (Section G)
PHILLIPS-MEDISIZE CORPORATION
415 red cedar street
medical device manufacturing
menomonie WI 54751
Manufacturer Contact
caroline rosewell
lilly corporate center
indianapolis, IN 46285
3172764376
MDR Report Key6147575
MDR Text Key61539968
Report Number1819470-2016-00312
Device Sequence Number1
Product Code FMF
Combination Product (y/n)N
PMA/PMN Number
K151686
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,consum
Type of Report Initial,Followup
Report Date 12/16/2016
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received12/06/2016
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Other
Device Model NumberMS9557
Device Lot Number0803D06
Was Device Available for Evaluation? No
Was the Report Sent to FDA?
Event Location No Information
Date Manufacturer Received12/13/2016
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured03/21/2008
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial

Patient Treatment Data
Date Received: 12/06/2016 Patient Sequence Number: 1
Treatment
INSULIN HUMAN
-
-